Hepatic Safety of Statin Use in Neurology Inpatients
A Retrospective Study on the Hepatic Safety of Statin Use in Neurology Inpatients
Shanghai Yueyang Integrated Medicine Hospital
2,000 participants
Aug 10, 2024
OBSERVATIONAL
Conditions
Summary
This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.
Eligibility
Inclusion Criteria3
- Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.
- Age ≥18 and ≤85 years old, both sexes.
- Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.
Exclusion Criteria3
- Incomplete medical history.
- days ≤ patients with \< 7 days of prior statin use.
- Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06592196